CellforCure is a France-based contract development and manufacturing organization (CDMO) focused on advanced therapy medicinal products (ATMPs), with core expertise in cell and gene therapies such as CAR‑T and other immune cell therapies. The company supports biotechnology and pharmaceutical developers with compliant, scalable production for clinical and commercial supply.
Its services span process and analytical development, technology transfer, GMP manufacturing, in‑house quality control, and batch release under European regulatory frameworks, with capabilities to support multinational studies and market supply. CellforCure’s operations emphasize end‑to‑end integration, from starting material handling through final drug product, serving both autologous and allogeneic therapy programs.
Seeking buyer to preserve cell & gene therapy manufacturing after funding slowdown, project cancellations and US relocation. Takeover sought in coming months; employee support prioritized.
The partnership enhances global CDMO capacity, offering integrated services for ATMP development and manufacturing, leveraging expertise and infrastructure across the U.S. and Europe.
